ARCHIVES

Novartis Begins Study Of Femara And Zometa In Postmenopausal Early Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 12 | December 27, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: House Passes Bill Extending Saccharin Status To 1981; Execs No Enthusiastic Over New SES

August 3, 1979

NCCS Networker Volume 3 Issue 2, Spring 1989

April 13, 1989

In Brief: DeVita, FDA Chief Help Kill California Bill Legalizing Laetrile Wit committee Testimony

August 26, 1977

NCI Committed To 50 Percent Mortality Reduction By 2000; DCPC Board Hears How That Will Be Done

January 20, 1984

NCI May Support More Training Of Cancer Surgeons

May 23, 1975

FDA Advisors Recommend Approval Of Taxol for Node-Positive Breast Cancer

September 24, 1999